Opsonic antibodies to the surface M protein of group a streptococci in pooled normal immunoglobulins (IVIG): Potential impact on the clinical efficacy of IVIG therapy for severe invasive group a streptococcal infections

Infection and Immunity

Volumn 66, Issue 5, 1998, Pages 2279-2283

  Basma, Hesham ^a,b   Norrby Teglund, Anna ^a   McGeer, Allison ^c   Low, Donald E ^c   El Ahmedy, Omar ^a,b   Dale, James B ^a   Schwartz, Benjamin ^d   Kotb, Malak ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; STREPTOCOCCUS ANTIBODY; SURFACE M PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BACTERIAL IMMUNITY; BACTERIAL VIRULENCE; CLINICAL ARTICLE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; STREPTOCOCCUS GROUP A;

EID: 0031924674     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.5.2279-2283.1998     Document Type: Article

References (45)

1. Barry, W., L, Hudgins, S. T. Donta, and E. L. Pesanti. 1992. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 267:3315-3316.
2. Beachey, E. H., M. Bronze, J. B. Dale, W. Kraus, T. Poirier, and S. Sargent. 1988. Protective and autoimmune epitopes of streptococci M proteins. Vaccine 6:192-196.
3. Beachey, E. H., and J. M. Seyer. 1982. Primary structure and immunochemistry of group A streptococcal M proteins. Semin. Infect. Dis. 4:401-410.
4. Bisno, A. L., and D. L. Stevens. 1996. Streptococcal infections of skin and soft tissues. N. Engl. J. Med. 334:240-245.
5. Burns, E. H., Jr., A. M. Marciel, and J. M. Musser. 1996. Activation of 66-kilodalton human endothelial cell matrix metalloprotease by Strepiococcus pyogenes extracellular cysteine protease. Infect. Immun. 64:4744-4750.
6. Cleary, P. P., E. L. Kaplan, J. P. Handley, A. Wlazlo, M. H. Kim, A. R. Hauser, and P. M. Schlievert. 1992. Clonal basis for resurgence of serious Streptococcus pyogencs disease in the 1980s. Lancet 339:518-521.
7. Davies, H. D., A. McGeer, B. Schwartz, K. Green, D. Cann, A. E. Simor, D. E. Low, and Ontario Streptococcal Study Group. 1996. Invasive group A streptococcal infections in Ontario, Canada. N. Engl. J. Med. 335:547-554.
8. Demers, B., A.-E. Simor, H. Vellend, P. M. Schlievert, S. Byrne, F. Jamieson, S. Valmsley, and D. E. Low. 1993. Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin. infect. Dis. 16:792-800.
9. Ferrieri, P. 1991. Microbiological features of current virulent strains of group A streptococci. Pediatr. Infect. Dis. J. 10:S20-S24.
10. Fischer, G. W., S. R. Wilson, and K. W. Hunter. 1982. Functional characteristics of a modified immunoglobulin preparation for intravenous administration: summary of studies of opsonic and protective activity against group B streptococci. J. Clin. Immunol. 2:31-35S.
11. Fischetti, V. A. 1991. Streptococcal M protein. Sci. Am. 264:58-65.
12. Gaworzewska, E., and G. Colman. 1988. Changes in the pattern of infection caused by Streptococcus pyogenes. Epidemiol. Infect. 100:257-269.
13. Haanes-Fritz, E., W. Kraus, V. Burdett, J. B. Dale, E. H. Beachey, and P. P. Cleary. 1988. Comparison of the leader sequences of 4 group A streptococcal M protein genes. Nucleic Acids Res. 10:4667-4677.
14. Hall, P. D. 1993. Immunomodulation with intravenous immunoglobulin. Pharmacotherapy 13:564-573.
15. Herwald, H., M. Collin, W. Muller-Esterl, and L. Bjorck. 1996. Streptococcal cysteine proteinase releases kinins: a virulence mechanism. J. Exp. Med. 665-673.
16. Holm, S. E., A. Norrby, A. M. Bergholm, and M. Norgren. 1992. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J. Infect. Dis. 166:31-37.
17. Isphani, P., F. E. Donald, and A. J. D. Aveline. 1988. Streptococcus pyogenes bacteremia: an old enemy subdued, but not defeated. J. Infect. 16:37-46.
18. Janeway, C. A., J. F. Emnders, and J. L. Oncley. 1946. Use of fraction II-3 in the preparation of serum gammuglobulin (human). Memorandum to Division of Medical Sciences, National Research Council.
19. Kapur, V., M. W. Majesky, L.-L. Li, R. A. Black, and J. M. Musser. 1993. Cleavage of interleukin 1β (IL-1β) precursor to produce active IL1-β by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proc. Natl. Acad. Sci. USA 90:7676-7680.
20. Kaul, R., A. McGeer, A. Norrby-Teglund, M. Kotb, and D. E. Low. 1995. Intravenous immunoglobulin (IVIG) therapy in streptococcal toxic shock syndrome (STSS): results of a matched case-control study, abstr. LM68. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
21. Kaveri, S. V., L. Mouthon, and M. D. Kazatchkine. 1994. Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases. J. Neurol. Neurosurg. Psychiatry 57(Suppl.):6-8.
22. Kotb, M. 1995. Bacterial pyrogenic exotoxins as superantigens. Clin. Microbiol. Rev. 8:411-426.
23. Kraus, W., J. B. Dale, and E. H. Beachey. 1990. Identification of an epitope of type I streplococcal M protein that is shared with a 43-kD protein of human myocardium and renal glomeruli. J. Immunol. 145:4089-4093.
24. Lancefield, R. L. 1962. Current knowledge of the type-specific M antigens of group A streptococci. J. Immunul. 89:307-313.
25. Low, D. E., B. Schwartz, and A. McGeer. The reemergence of severe group A streptococcal disease: an evolutionary perspective. In Emerging pathogens. Proceedings of the 1996 International Congress on Antimicrobial Agents and Chemotherapy, in press.
26. Marrack, P., and J. Kappler. 1990. The staphyloeoccal enterotoxins and their relaiives. Science 248:705-711.
27. McGeer, A., et al. Unpublished data.
28. Miethke, T., C. Wahl, D. Regele, H. Gaus, K. Heeg, and H. Wagner. 1993. Superantigen mediated shock: a cytokine release syndrome. Immunobiology 189:270-284.
29. Musser, J. M., V. Kapur, J. Szeto, X. Pan, D. S. Swanson, and D. R. Martin. 1995. Genetic diversity and relationship among Streptococcus pyogenes strains expressing serotype M1 protein: recent intercontinental spread of a subclone causing episodes of invasive disease. Infect. Immun. 63:994-1003.
30. Nadal, D., R. P. Lauener, C. P. Braegger, A. Kaufhold, B. Simma, R. Lutticken, and R. A. Seger. 1993. T cell activation and cytokine release in streplococcal toxic shock-like syndrome. J. Pediatr. 122:727-729.
31. Newburger, J. W., M. Takahashi, J. C. Burns, A. S. Beiser, K. J. Chung, C. E. Dufly, M. P. Glode, W. H. Mason, V. Reddy, S. P. Sanders, S. T. Shulman, J. W. Wiggins, R. V. Hicks, D. R. Fulton, A. B. Lewis, D. Y. M. Leung, T. Colton, F. S. Rosen, and M. E. Melish. 1986. The treatment of Kawasaki syndrome with intravenous gamma globulin. N. Engl. J. Med. 315:341-347.
32. Norrby-Teglund, A., H. Basma, J. Andersson, A. McGeer, D. E. Low, and M. Kotb. 1998. Varying tilers of neutralizing antibodies to streptoeoccal superantigens in different preparations of normal polyspecific immunoglobulin G (IVIG): implications for therapeutic efficacy. Clin. Infect. Dis. 26:631-638.
33. Norrby-Teglund, A., R. Kaul, D. E. Low, A. McGeer, J. Andersson, U. Andersson, and M. Kotb. 1996. Evidence for the presence of streptococcal superantigcn-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect. Immun. 64:5395-5398.
34. Norrby-Teglund, A., R. Kaul, D. E. Low, A. McGeer, D. W. Newton, J. Andersson, U. Andersson, and M. Kotb. 1996. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streplococcal superantigen-induccd T cell profiteration and cytokine production. J. Immunol. 156:3057-3064.
35. Norrby-Teglund, A., M. Norgren, S. E. Holm, U. Andersson, and J. Andersson. 1994. Similar cytokine induction profiles of a novel streptococcal exotoxin, MF, and pyrogenic exotoxins A and B. Infect. Immun. 62:3731-3738.
36. Ogawa, M., S. Ueda, N. Anzai, K. Ito, and M. Onto. 1995. Toxic shock syndrome after staphylococcal pneumonia treated with intravenous immunoglobulin. Vox Sang. 68:59-60.
37. Schlievert, P. M. 1993. Role of superantigens in human diseases. J. Infect. Dis. 167:997-1002.
38. Skansen-Saphir, U., J. Andersson, L. Bjork, and U. Andersson. 1994. Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG. Eur. J. Immunol. 24:916-922.
39. Stegmayer, B., S. Björck, S. Holm, J. Nisell, A. Rydvall, and B. Settergren. 1992. Septic shock induced by group A streptoeoccal infection: clinical and therapeutic aspects. Scand. J. Infect. Dis. 24:589-597.
40. Stevens, D. L. 1992. Invasive group A streptococcus infections. Clin. Infect. Dis. 14:2-13.
41. Sullivan, G. W., and G. L. Mandell. 1991. The role of cytokines in infection. Curr. Opin. Infect. Dis. 4:344-349.
42. Takei, S., Y. K. Arora, and S. M. Walker. 1993. Intravenous immunoglobulin contains specific antibodies inhibitory to activations of T cells by staphylococcal toxin superantigens. J. Clin. Invest. 91:602-607.
43. Walley, K. R., N. W. Lukacs, T. J. Standiford, R. M. Strieter, and S. L. Kunkel. 1996. Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect. Immun. 64:4733-4738.
44. Weisman, L. E., D. F. Cruess, and G. W. Fischer. 1994. Opsonic activity of commercially available standard intravenous immunoglobulin preparations. Pediatr. Infect. Dis. J. 13:1122-1125.
45. Working Group on Severe Streptococcal Infections. 1993. Defining the group A Streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA 269:390-391.